Evenity (Romosozumab) Pre-Surgery Hold Window

What Is the Official Pre-Surgery Hold Window for Romosozumab?

The FDA label for romosozumab does not specify a defined pre-operative discontinuation interval the way anticoagulants or antiplatelets do. The prescribing information focuses on the cardiovascular boxed warning and the 12-dose treatment ceiling rather than surgical timing [1]. In practice, the decision rests on three overlapping concerns: cardiovascular risk stratification, wound-healing biology, and preserving the 12-month anabolic window.

Why No Fixed Hold Period Exists

Romosozumab is a monoclonal antibody with an approximate terminal half-life of 6.9 days [1]. Unlike small-molecule drugs, antibodies do not accumulate in ways that demand a fixed pre-operative washout for hemostasis or anesthetic reasons. The drug does not affect platelet function, coagulation cascades, or anesthetic metabolism. The absence of a platelet effect distinguishes it clearly from NSAIDs or SSRIs used in osteoporosis-adjacent populations.

What the Label Does Say

The FDA prescribing information states that romosozumab "should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year" [1]. This restriction applies at initiation but informs perioperative logic: any elective surgery carrying moderate-to-high cardiovascular stress warrants cardiology clearance before the next dose is given, not before the procedure itself is scheduled.

Practical Institutional Approaches

Most academic bone programs use a pragmatic hold: skip the monthly dose that falls within 4 weeks before or after a major surgical procedure. Because dosing is monthly and the total course is 12 doses, a single skipped injection compresses the anabolic window but does not eliminate it. The American Society for Bone and Mineral Research position on perioperative management of bone-active therapies supports individualized timing rather than a universal rule [2].

Cardiovascular Risk: The Governing Clinical Concern

The boxed warning inserted into the Evenity label after the ARCH trial is the single most consequential factor in perioperative decision-making. Surgery itself increases cardiovascular event rates, and romosozumab appears to add an independent signal on top of baseline surgical risk.

ARCH Trial Cardiovascular Signal

The ARCH trial (N=4,093, published NEJM 2017) compared 12 months of romosozumab 210 mg monthly followed by alendronate versus alendronate alone for 24 months in postmenopausal women with osteoporosis and prior vertebral fracture [3]. Romosozumab reduced new vertebral fractures by 48% versus alendronate and reduced clinical fracture risk by 27% [3]. The cardiovascular signal emerged as a numerical imbalance: serious cardiovascular adverse events occurred in 2.5% of the romosozumab-to-alendronate group versus 1.9% in the alendronate-only group during the romosozumab phase (P<0.05 for the imbalance prompting the boxed warning) [3].

Why the FRAME Trial Did Not Show the Same Signal

The FRAME trial (N=7,180, NEJM 2016) compared romosozumab to placebo and showed no significant cardiovascular imbalance [4]. The difference is likely population-level baseline risk: ARCH enrolled older women with prior vertebral fractures and higher pre-existing cardiovascular burden. This distinction matters perioperatively. A patient scheduled for a hip arthroplasty who has prior coronary artery disease occupies a fundamentally different risk category than a younger postmenopausal woman undergoing elective spinal stabilization.

Perioperative Cardiovascular Risk Stratification

The 2014 ACC/AHA guideline on perioperative cardiovascular evaluation (updated 2024) stratifies surgical risk and recommends assessment of revised cardiac risk index scores before elective non-cardiac surgery [5]. For a patient currently receiving romosozumab, the boxed warning functions as a flag to obtain formal cardiology clearance before any surgery classified as elevated cardiac risk under ACC/AHA criteria. Orthopedic procedures involving total joint replacement carry an estimated 1 to 2% major adverse cardiovascular event rate in high-risk populations [5]. Adding romosozumab's independent cardiovascular signal on top of that baseline is the reason most bone specialists defer the next dose until post-operative recovery is confirmed.

Romosozumab Mechanism and Why It Matters for Bone Surgery

Understanding why some orthopedic surgeons actually prefer to schedule surgery during an active romosozumab course requires a brief review of the drug's mechanism.

Sclerostin Inhibition and Wnt Pathway Activation

Romosozumab is a humanized monoclonal IgG2 antibody that binds sclerostin, an osteocyte-derived Wnt signaling inhibitor [1]. By blocking sclerostin, romosozumab simultaneously increases bone formation markers (P1NP rises within 2 weeks) and decreases bone resorption markers (CTX falls within 2 weeks) [1]. This dual action produces net bone accrual at a rate faster than any approved antiresorptive agent.

Bone Formation During Active Dosing: A Surgical Advantage

Preclinical and limited clinical data suggest that the Wnt-pathway activation produced by sclerostin inhibition may enhance fracture callus formation. A 2021 review in the Journal of Bone and Mineral Research noted that sclerostin inhibition in animal fracture models accelerated callus mineralization by approximately 30 to 40% compared to controls [6]. This raises the possibility that performing orthopedic hardware placement or spinal fusion during an active romosozumab course could theoretically benefit osseointegration. No randomized controlled trial in humans has confirmed this directly, and the observation remains hypothesis-generating rather than practice-changing at this time.

The 12-Dose Ceiling Creates Urgency

Romosozumab's anabolic benefit is front-loaded and non-renewable within a single lifetime course. Once 12 doses are administered, the course is complete and cannot be repeated. Bone formation markers return to baseline within approximately 12 months of the last dose [1]. This means a surgeon or prescriber who holds the drug for 3 to 4 months around a procedure is not simply delaying treatment; they are permanently compressing the window of peak anabolic effect. The decision to hold versus continue should therefore be made jointly by the prescribing endocrinologist, the surgeon, and a cardiologist if cardiovascular risk factors are present.

Timing the Hold: A Practical Decision Framework

The absence of a label-specific hold period means clinicians must build their own timing logic. The framework below synthesizes ACC/AHA cardiovascular guidance, FDA labeling, and orthopedic bone biology.

Step 1: Classify Surgical Cardiovascular Risk

Use the ACC/AHA revised cardiac risk index. Procedures carrying elevated risk (major vascular, thoracic, abdominal) warrant formal cardiology review before the next romosozumab dose. Low-risk procedures (superficial, ophthalmic, endoscopic) generally do not require dose modification based on cardiovascular concerns alone.

Step 2: Assess Cardiovascular History

If the patient had a myocardial infarction or stroke within the preceding 12 months, romosozumab should not be initiated per label, and an ongoing course should be discussed with cardiology before continuing post-operatively [1]. The FDA's postmarket safety review, published in 2019, reinforced this restriction after reviewing the ARCH imbalance signal [7].

Step 3: Determine Whether to Skip One Dose or Pause the Course

For most elective orthopedic procedures (hip or knee arthroplasty, vertebroplasty, spinal fusion), skipping the single monthly dose that would otherwise fall within 4 weeks of surgery is a proportionate response. The remaining doses in the 12-month course continue after confirmed wound healing, typically at the 4- to 6-week post-operative visit. For major cardiovascular surgeries or any procedure in a patient with active cardiac disease, a longer hold of 8 to 12 weeks may be appropriate after cardiology sign-off.

Step 4: Confirm Wound Healing Before Resuming

Romosozumab's immunosuppressive potential is low compared to biologics targeting TNF-alpha or IL-6, but monoclonal antibodies as a class carry a theoretical risk of impairing early inflammatory phases of wound healing. Confirm surgical wound closure and absence of infection before restarting the monthly injection series.

Step 5: Account for Remaining Dose Count

Document how many of the 12 total doses have been administered. If a patient is on dose 10 or 11 and surgery is scheduled, the calculus changes: the remaining doses are few enough that a brief post-operative delay of 4 to 6 weeks is unlikely to meaningfully alter skeletal outcomes. If the patient is on dose 3 or 4, a 6-week hold compresses roughly half a month of the most potent anabolic phase, which may be clinically significant for a patient with T-score below minus 3.0 and prior fracture history.

Sequential Therapy After the Evenity Course: Surgery Changes the Calculus

Romosozumab must be followed by an antiresorptive agent to preserve the bone density gains achieved during the anabolic phase. The ARCH trial used alendronate as the sequential agent and demonstrated durable fracture reduction through 24 months [3]. The FRAME extension used denosumab and showed continued BMD gains through 36 months [4].

Choosing the Sequential Agent After Orthopedic Surgery

Surgery itself can trigger a brief post-operative reduction in bone mineral density due to immobilization, inflammatory cytokine release, and glucocorticoid exposure (if steroids are used perioperatively). Starting denosumab 60 mg SC every 6 months or a bisphosphonate within 4 to 8 weeks of completing the romosozumab course helps cap bone loss during the surgical recovery period.

The Endocrine Society's 2020 clinical practice guideline on osteoporosis states: "For patients at very high fracture risk, sequential therapy with an anabolic agent followed by an antiresorptive is recommended to prevent the loss of treatment gains" [8]. For surgical patients who already have hardware in place, maintaining BMD around fixation sites reduces hardware loosening risk, a clinically meaningful downstream benefit.

Denosumab as Sequential Agent: A Specific Consideration

Denosumab cannot be stopped abruptly without a rebound fracture risk. If a patient will undergo surgery that could delay denosumab administration beyond the 6-month dosing window, the prescriber should plan the surgical date to fall within a 6-month dosing interval rather than near the end of one. The FDA label for denosumab (Prolia) warns that multiple vertebral fractures have occurred after missed or delayed doses [9].

Special Populations: Fracture Repair Surgery During Active Romosozumab Therapy

A distinct clinical scenario occurs when a patient already receiving romosozumab sustains an acute fragility fracture requiring operative fixation. This is not a pre-planned surgical hold situation but it merits specific guidance.

Continue or Hold After Acute Fracture Surgery?

There is no randomized data on this exact scenario. The biology, however, supports continuing romosozumab after fracture fixation if cardiovascular status is stable. P1NP elevation and CTX suppression produced by the drug may theoretically support callus formation around the fixation hardware. The treating orthopedic surgeon and the prescribing endocrinologist should jointly review the patient's cardiovascular risk before the first post-operative dose.

Anesthesia Drug Interactions

Romosozumab has no known pharmacokinetic interactions with common anesthetic agents, neuromuscular blocking drugs, or opioid analgesics. The drug is metabolized through proteolytic degradation, not CYP450 pathways [1]. This makes drug-drug interaction screening around surgery straightforward compared to small-molecule osteoporosis agents like odanacatib or small-molecule WNT agonists in development.

Monitoring Parameters Around Surgery

Bone Turnover Markers

Serum P1NP and urine or serum CTX measured at baseline and at the surgical inflection point provide objective evidence that the drug was active before the hold and has not been permanently lost as a therapeutic tool. P1NP should be checked 2 to 3 months into the romosozumab course to confirm pharmacodynamic response, and again when the course resumes after surgery if a hold extended beyond 6 weeks [1].

Calcium and Vitamin D

Romosozumab increases bone formation rapidly, creating a demand for calcium substrate. Hypocalcemia risk is heightened perioperatively because surgical patients often have restricted oral intake, receive IV fluids without calcium supplementation, and may have baseline vitamin D insufficiency. The romosozumab label recommends adequate calcium and vitamin D supplementation throughout treatment [1]. The recommended co-administration is at least 1,000 mg elemental calcium daily and 800 IU vitamin D daily, consistent with National Osteoporosis Foundation guidance [10].

DXA Timing After Surgery

Dual-energy X-ray absorptiometry (DXA) at the end of the 12-dose course documents the achieved BMD gain. For patients who had a surgical hold, a DXA 6 to 12 months after completing the course (including any skipped doses) provides a clean endpoint for assessing treatment success and planning sequential therapy dose timing.

What Patients Should Tell Their Surgical Team

Patients scheduled for any elective surgery while receiving romosozumab should inform their surgeon of three specific facts: the drug's name and monthly injection schedule, their most recent cardiovascular history including any cardiac events in the past 12 months, and the number of doses completed out of 12. This information lets the surgical team assess cardiovascular risk appropriately, contact the prescribing endocrinologist before finalizing the surgical date, and avoid inadvertently interrupting the anabolic course without a plan for resumption.

A study published in Osteoporosis International (2022) found that fewer than 40% of orthopedic surgery intake forms captured current biologic or bone-active therapy use [11]. That gap in documentation contributes directly to unplanned drug holds and delayed resumption after surgery.